Extracellular vesicle-derived miR-146a as a novel crosstalk mechanism for high-fat induced atherosclerosis by targeting SMAD4
View abstract on PubMed
Summary
This summary is machine-generated.Exosomes carrying miR-146a promote atherosclerosis by targeting SMAD4 and activating the p38 MAPK pathway. Inhibiting miR-146a effectively reduced atherosclerosis in mice, suggesting its therapeutic potential.
Area Of Science
- Cardiovascular Research
- Molecular Biology
- Cell Biology
Background
- Exosome-miR-146a is elevated in atherosclerosis (AS) patients.
- The precise role and mechanism of exosome-miR-146a in AS remain unclear.
Purpose Of The Study
- Investigate exosome release mechanisms.
- Elucidate the role and molecular mechanisms of exosome-miR-146a in AS.
Main Methods
- Isolated exosomes from ox-LDL treated macrophages.
- Identified exosome release regulators (NMMHC IIA, HSP70).
- Assessed exosome uptake and effects on HVSMCs.
- Determined miR-146a targets (SMAD4) and pathway modulation (p38 MAPK).
- Utilized a mouse model of AS to evaluate exosome-miR-146a impact.
Main Results
- Foam cells showed increased miR-146a expression.
- Exosomes from macrophages were internalized by HUVECs.
- miR-146a directly targeted SMAD4, modulating the p38 MAPK pathway and causing HUVEC damage.
- Exosome-miR-146a promoted HVSMC proliferation and migration.
- Inhibition of miR-146a reduced AS in mice, while its increase worsened AS.
Conclusions
- Exosome-miR-146a plays a critical role in AS pathogenesis.
- miR-146a is a potential therapeutic target for AS.
- Further research is needed to understand in vivo exosome-miR-146a regulation for therapeutic strategies.

